Jieyang

People with end stage kidney disease ESKD who require dialysis face a much higher risk of cardiovascular disease compared to the general population, with cardiac issues causing 58% of deaths in this group. However, while aspirin is known to reduce cardiovascular problems in the general population, there is limited evidence about its effects in dialysis patients. The ASPIrin to Reduce Event in Dialysis ASPIRED trial aims to study whether taking low-dose aspirin can safely improve cardiovascular outcomes in people with ESKD receiving dialysis. This study is a multi-center, double-blind, randomized controlled trial that will compare daily low-dose aspirin 100 mg to a placebo pill in patients undergoing dialysis. The trial uses an existing dialysis registry platform to screen, recruit, and collect data during routine clinical care, minimizing participant burden and study costs. Randomization is managed through a secure web-based system, and follow-up visits occur every six months as part of regular clinic visits. The trial is expected to last approximately five years and includes oversight by an independent safety and monitoring board. Participants will be involved in regular six-monthly clinic visits where their health will be monitored as part of their usual dialysis care. Researchers will track the occurrence of major cardiovascular events, including heart attacks, strokes, vascular complications, and deaths, throughout the study period. Data will be collected from routine clinical procedures and the dialysis registry to evaluate outcomes. Safety and efficacy will be closely monitored, and the study will follow participants for up to five years to assess the long-term effects of aspirin use in this population.

Researchers are evaluating Keverprazan-amoxicillin dual therapy to improve treatment for Helicobacter pylori HP infection, which is linked to several serious diseases. Traditional quadruple treatments can cause severe side effects, high costs, and poor compliance. Keverprazan, a new potassium acid blocker, may offer a stronger and longer-lasting acid inhibition that is not affected by genetic differences, potentially improving eradication rates and patient experience. This study aims to compare different doses and durations of Keverprazan-amoxicillin dual therapy to find the most effective approach. The trial compares three treatment regimens a 14-day course with high-dose amoxicillin 1000 mg three times daily, a 14-day course with a lower dose of amoxicillin 1000 mg twice daily, and a 10-day course with high-dose amoxicillin 1000 mg three times daily. All groups receive Keverprazan hydrochloride tablets 20 mg twice daily orally. These regimens are studied to assess their effectiveness in eradicating HP infection while monitoring side effects and treatment adherence. Participants are adults aged 18 to 75 years who have tested positive for HP infection and may have failed previous eradication attempts. They will take their assigned therapy and attend study visits for monitoring. Researchers will measure HP eradication rates six weeks after treatment, along with any adverse events and medical costs. The study includes safety monitoring and adherence checks to ensure reliable results over the treatment and follow-up periods.